UPC appeals after three years: Early indications on appeal success rates

​
July 15, 2026

The UPC has now been running for three years. With first instance proceedings typically taking around one year and appeals taking a similar period, now is perhaps the first opportunity to, cautiously, look at a sufficiently mature body of Court of Appeal decisions and seek to identify patterns.

Appeals in the UPC, as for most courts, are to a material extent self-selecting. Parties are less likely to appeal clear cut decisions, while cases with a realistic prospect of success are more likely to proceed. Even though the UPC requires no permission to appeal final decisions, the fact that appeals at the UPC do not automatically have a suspensory effect (as in the EPO, for instance) or offer material procedural advantage, would reduce incentives for parties to file more ‘ambitious’ appeals. Moreover, additional disagreement between first instance and appeal is also unsurprising at this stage, while the UPC remains a relatively young court and its case law is still settling. Against that backdrop, an overturn rate of just over half for both substantive appeals and appeals on the grant of a preliminary injunction (56% or five out of nine for substantive appeals; 56% or 9 out of 16 for appeals on preliminary injunctions) feels broadly in line with what one would expect.

UPC Court of Appeal: overturn rate by appeal type
Substantive appeals
Preliminary injunction appeals
Overturn rate
56%
56%
Decisions overturned
5 of 9
9 of 16

Within both categories of appeals, decisions are being overturned for a range of reasons. Some notable developments are as follows:

  • On provisional injunction appeals, the Court of Appeal has generally conducted a detailed substantive review of the questions of novelty and infringement, mirroring what seems to have become common at first instance as well. It is not at all unusual for judgments to include 20-30 pages (or more) on the assessment of validity and infringement.  However, the consideration of urgency has also been a source of reversal on appeal.  Given that suspensive effect is not generally granted for appeals of provisional injunctions, the value of an appeal over-turning a provisional injunction seems rather limited since in the meantime there is time for the first instance substantive decision to be either already available or expected soon.
  • For substantive appeals, again there is a range of reasons why the appeal outcome varied from first instance. Sometimes (as also in the first successful PI appeal of Nanostring v 10x Genomics) a difference in claim construction leads to a difference in conclusion on either validity or infringement.
  • The Kodak v Fujifilm appeal was particularly interesting as much of the substantive analysis on appeal differed little from that at first instance, but the Court of Appeal recognised a prior user right in respect of Germany that the first instance had not considered substantiated, while in respect of the UK the defendants were considered not the parties responsible for the UK acts.
  • On the patentee-friendliness of the Court of Appeal, it is interesting that despite over half the appeals succeeding, the overall rate of success rate of patentees is unchanged following appeals. In five of the nine first instance decisions that were appealed, there had been a finding that a patent was valid and infringed. Following appeal, there was found to be a valid and infringed patent in five of the nine cases. This would suggest that overall the Court of Appeal is no more pro- or anti-patentee than the first instance courts.
UPC Court of Appeal: patentee success rate before and after appeal
First instance decisions
On appeal
Valid and infringed
5 of 9
5 of 9
UPC Court of Appeal: preliminary injunction appeals
OverturnedUpheld
PartiesDateReferenceFirst Instance – injunction grantedAppeal – decision on injunction
NanoString v 10x Genomics26 February 2024
UPC_CoA_335/2023
Preliminary injunction grantedOverturned – patent likely invalid for obviousness
SES-imagotag SA v. Hanshow Technology13 May 2024
UPC_CoA_1/2024
Preliminary injunction refusedUpheld
Mammut Sports Group v. Ortovox Sportartikel25 September 2024
UPC_CoA_182/2024
Preliminary injunction grantedUpheld
SharkNinja v. Dyson03 December 2024
UPC_CoA_297/2024
Preliminary injunction grantedOverturned – patent likely not infringed
Alexion Pharmaceuticals, Inc. v. Samsung Bioepis & Amgen20 December 2024
UPC_CoA_402/2024
UPC_CoA_405/2024
Preliminary injunction refused – patent likely to be found invalid in parallel EPO proceedingsUpheld
Abbott Diabetes Care Inc. v. Sibio Technology Limited14 February 2025
UPC_CoA_382/2024
Preliminary injunction refused – patent held likely invalid for added matterOverturned – patent found likely to be valid
Sumi Agro Europe v. Syngenta04 March 2025
UPC_CoA_523/2024
Preliminary injunction grantedUpheld
Insulet Corporation v. EOFLOW01 May 2025
UPC_CoA_768/2024
Preliminary injunction refused – patent likely not novelOverturned – CoA found patent to be likely valid and infringed
Boehringer Ingelheim v Zentiva13 August 2025
UPC_CoA_446/2025
UPC_CoA_520/2025
Preliminary injunction refused – found to be lack of imminent infringementOverturned – Preliminary injunction granted on urgency grounds
OTEC v. Steros07 November 2025
UPC_CoA_579/2025
Preliminary injunction grantedOverturned – patent likely not infringed
Barco v. Yealink28 November 2025
UPC_CoA_317/2025
Preliminary injunction refused – lack of urgencyUpheld
ONWARD Medical v. Niche Biomedical, Inc.27 March 2026
UPC-COA-898/2025
Preliminary injunction refusedUpheld
Sinocare v. Abbott30 March 2026
UPC-COA-899/2025
Preliminary injunction grantedUpheld
Abbott v. Sinocare17 April 2026
UPC-COA-901/2025
Preliminary injunction refused – patent likely not infringedOverturned – CoA found patent likely valid and infringed
Merz Pharmaceuticals v. Viatris Santé27 April 2026
UPC-COA-917/2025
Preliminary injunction refused – lack of urgency; proportionality of injunctionOverturned on urgency and proportionality grounds
Occlutech v Lepu Medical18 June 2026
UPC_CoA_907/2025
Preliminary injunction refused – patent likely not infringedOverturned – patent likely infringed
UPC Court of Appeal: substantive appeals
OverturnedUpheldOther outcome
PartiesDateReferenceFirst InstanceAppeal – ValidityAppeal – Infringement
Expert e-Commerce GmbH v. Seoul Viosys2 October 2025
UPC_CoA_764/2024
Patent found valid and infringedOverturned – patent invalid for added matterNot considered
Philips v. Belkin3 October 2025
UPC_CoA_534/2024
UPC_CoA_19/2025
UPC_CoA_683/2024
Patent found valid and infringedUpheld.Upheld
Seoul Viosys v. expert e-Commerce6 November 2025
UPC_CoA_762/2024
UPC_CoA_773/2024
Patent held invalid for added matterUpheldNot considered
Amgen, Inc. v. Sanofi & Regeneron25 November 2025
UPC_CoA_528/2024
UPC_CoA_529/2024
Patent found invalid for lack of inventive stepOverturned – patent found to be validStayed at first instance
Meril v Edwards Lifesciences25 November 2025
UPC_CoA_530/2024 UPC_CoA_464/2024
Patent found valid and infringedUpheldUpheld
VMR Products LLC v. NJOY Netherlands B.V.5 January 2026
UPC_CoA_71/2025
Patent found invalid for lack of inventive stepUpheldNot considered
Rematec GmbH & Co KG v Europe Forestry B.V.18 February 2026
UPC_CoA_302/2025
UPC_CoA_305/2025
Patent found invalid for lack of noveltyOverturnedN/A (no first instance findings, however the CoA held the patent was infringed and granted injunction)
Hefei Xinhu v. Grundfos27 May 2026
UPC_CoA_622/2025
Patent found valid and infringedOverturned – patent partly revokedN/A (relevant claims of patent revoked)
Kodak v Fujifilm2 June 2026
UPC-CoA-312/2025
UPC-CoA-333/2025
UPC-CoA-880/2025
UPC-CoA-882/2025
Patent found valid and infringedUpheldOverturned

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Quantum IP Strategy: Own control Points, Not Patent Counts
14 October 2026
In quantum, the strongest portfolios will not be the biggest. Stuart Malcolm sets out six moves for owning the control points the market cannot route around, and the questions investors will ask.
#
Consulting
​
Targeted, Not Transformative: The UKIPO’s Considered Course on SEPs
13 October 2026
Andrew Sharples analyses the UKIPO's response to its SEP consultation, exploring proposed changes to FRAND dispute resolution, SEP transparency and licensing guidance, and what they mean for SEP holders and implementers.
#
Consulting
​
Chinese Companies in European Patent Litigation
30 September 2026
Chinese companies are becoming increasingly active in European patent litigation, both as defendants and as patent owners enforcing their own rights. This article examines the growing role of Europe and the Unified Patent Court (UPC) in global patent disputes, highlighting key cases involving Chinese businesses and the strategic opportunities and risks that come with operating in European markets. It is the first in a series exploring the practical implications of European patent enforcement for Chinese companies.
#
Patenting
​
How to mitigate prior art traps for follow-on pharma patents
27 August 2026
Follow-on patents are increasingly important for pharmaceutical innovators. Learn how new EMA clinical trial disclosure rules create prior art risks and discover practical strategies to protect pharmaceutical IP and maximise patent value.
#
Consulting
​
Chinese companies and the UPC: from enforcement targets to strategic users
13 August 2026
Chinese companies are playing an increasingly significant role in UPC litigation, accounting for around 38% of infringement actions in 2025. While many remain defendants, a growing number are actively using the Unified Patent Court to enforce their own patent rights across Europe. The trend highlights the UPC's rising importance for Chinese businesses operating in sectors such as telecommunications, semiconductors, medical devices and renewable energy, and signals a shift in global patent enforcement strategy.
#
Patenting
​
Evaluating the environmental impact of patent AI.
31 July 2026
AI's environmental impact is rarely out of the headlines, but how does it compare to the benefits it delivers in practice? In this article, Laurence Brown examines the energy use of AI-assisted patent drafting, comparing it with traditional drafting workflows. While measuring AI's true environmental footprint is far from straightforward, the analysis suggests that AI-assisted patent drafting may already be more energy efficient, while delivering significant productivity gains for patent professionals.
#
Patenting
​
UPC appeals after three years: Early indications on appeal success rates
15 July 2026
Three years into the UPC, appeal overturn rates sit at 56% for both substantive and preliminary injunction cases, with Kodak v Fujifilm among the rulings reshaping outcomes on appeal.
#
Litigation
​
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
#
Litigation
​
Podcast: Building an AI-Native Law Firm
26 June 2026
On the Technically Legal podcast, EIP partner Laurence Brown discusses how Visser AI is redesigning patent workflows, letting the firm offer fixed fees without trading away speed or quality.
#
Patenting
​
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
#
Litigation
​
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
#
Consulting
​
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
#
Consulting
​
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
#
Consulting
​
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
#
Patenting
​
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
#
Patenting
​